

DAFTAR PUSTAKA

- Agarwal, R., Nissenson, A.R., Battle, D., 2003, Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States, *Am J Med.*, 115(4):291-7
- Anonim, 2006, *Drug Information Handbook*, 14th Ed., 487-490 ; 618-622, Lexi-comp, United State of America.
- Anonim, 2009^a, *British National Formulary*, 5th Ed., 517-521, RPS Publishing, London
- Anonim, 2009^b, *Drug Information Handbook*, 17th Ed., 487-490 ; 618-622, Lexi-comp, United State of America.
- Allredge, B.K., Corelli, R.L., dan Ernst, M.E., 2012, *Koda-Kimble and Young's Applied Therapeutics: The Clinical Use of Drugs*, 10th Ed., 764-795, Lippincott Williams & Wilkins, United State of America.
- Andrews, N.C., 2004, Anemia of inflammation : The cytokine hepcidin link, *J Clin Invest.*, 113(9):1251-3.
- Ajuria, L.J., Paul, L.K., Siegel, S., 2005, Anemia in Renal Disease, dalam Weiss, G., Victor, R.G., Chaim, H., 2005, *Anemia of Chronic Disease*, 671, Taylor and Francis Group, United States.
- Aronson, J.K., 2006, *Meyler's side effects of Drugs*, 7th Ed., 1284, Elsevier Oxford, United Kingdom.
- Azizi, M., Rousseau, A., Ezan, E., Guyune, T.T., Michelet, S., Grognet, J.M., Lenfant, M.I., Menard, J., 1996, Acute angiotensin-converting enzyme inhibition increases the plasma levels of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline, *J Clin Invest.*, 97:839-844.
- Bakris, G., Siomos, M., Richardson, D., 2000, ACE inhibition or angiotensin receptor blockade: Impact on potassium in renal failure, *Kidney Int.*, 58:2084-2092 cit. Sadjadi, S.A., James, I.M., Navin, J., Patricia, B., Su Su, H., 2009, A comparative study of the prevalence of hyperkalemia with the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers, *Therapeutics and Clinical Risk Management.*, 5:547-552.
- Barone, J.A., Desantis, E.R.H., 2000, Adverse Drug Reactions and Drug-Induced Disease, dalam Herfindall, E.T., Gourley, D.R., *Textbook of Therapeutic Drug and Disease Management*, 7th Ed., chapter2, Lippincott Williams and Wilkins, United State of America.

- Baxter, K., 2010^a, *Stockley's Drug Interactions*, 9th Ed., 19; 26-28; 743; 1051; 1238, Pharmaceutical Press, USA.
- Baxter, K., 2010^b, *Stockley's Drug Interactions Pocket Companion 2010*, 5; 50, Pharmaceutical Press, USA.
- Calis, K.A. dan Young, L.R., 2001, Clinical Analysis of Adverse Drug Reaction, dalam Atkison, Jr., A.J., Daniels, C.E., Dedrick, R.L., Grudzinskas, C.V., Markey, S.P., *Principles of Clinical Pharmacology*, 319-332, Academia Press, USA.
- Casati, S., Patrizia, P., Maria, R.C., Giorgio, G., Bruno, C., Michael, P., Claudio, P., 1987, Benefits and risks of protected treatment with human recombinant erythropoietin in patients having haemodialysis, *British Medical Journal*, 1017-1020.
- Chien, S.C., Li S.Y., Chen Y.T., Tsai L.W., Chen T.J., Chen T.W., Lin Y.C., 2013, Folic acid supplementation in end-stage renal disease patients reduces total mortality rate, *J Nephrol.*, 26(6):1097-104.
- Dahlan, M.S., 2013, *Besar Sampel dan Cara Pengambilan Sampel dalam Penelitian Kedokteran dan Kesehatan*, Salemba Medika, Jakarta.
- Direktorat Pengawasan Distribusi Produk Terapeutik dan PKRT, 2012, *Pedoman Monitoring Efek Smping Obat (MESO) bagi Tenaga Kesehatan*, 9, BPOM RI, Jakarta.
- De Maria, R., Testa, U., Luchetti, L., 1999, Apoptotic role of Fas/Fas ligand system in the regulation of erythropoiesis, *Blood.*, 93:796-803.
- Dipiro, J.T., Talbert, R.L., Yee, G.C., Matzke, G.R., Wells, B.G., Posey, L.M., 2008, *Pharmacotherapy: A Pathophysiologic Approach*, 7th Ed., 745-764 TheMcGraw-Hill Companies, Inc., USA.
- DiPiro, J.T., Talbert, R.L., Yee, Gary C., Matzke,GR., Wells,BG.,Posey,LM., 2005, *Pharmacoterapy: A Paathophysiologic Approach*, 6th Ed., 745-765, Mcgraw-Hill, New York, USA.
- Edward, I.R., 2001, *Adverse Drug Reactions*, dalam Van Boxtel,C.J., Santoso, B., Edward, I.R, 2001, *Drug Benefits and Risks International Textbook of Clinical Pharmacology*, 196-203, Jhon Wiley dan Sons.LTD.
- Edward, I.R., 1997, Pharmacological Basis of Adverse Drug Interactions, dalam Speight, T.M., Holford, N.H.G., 1997, *Avery's Drug Treatment*, 4th Ed., chapter 6;269-273 Adis International Limited, New Zealand.

- Elliott, W.J., 2006, *Drug interactions and drugs that affect blood pressure. J Clin Hypertens*, 8th Ed., 731–7, dalam Baxter, K., 2010^a, *Stockley's Drug Interactions*, 9th Ed., 1051, Pharmaceutical Press, USA.
- FactMed, 2014, Study of possible correlation between Hypercalcaemia And Erythropoietin Beta. Tersedia online <http://factmed.com/report-ERYTHROPOIETIN%20BETA-causing-HYPERCALCAEMIA.php> 24/3/2016 12:27.
- Flaharty, K.K., Grimm A.M., Vlasses P.H., 1989, Epoetin: human recombinant erythropoietin, *Clin Pharm*, 8(11):769-82.
- Gahart, B.L., Adrienne, R.N., 2014, *Intravenous Medications : A Handbook for Nurse and Health Profesionals*, 30th Ed., 470-471, Elsevier Inc mosby, Missouri Kolombia.
- Gregory, P.J., dan Kier. K.L., 2001, Medication Misadventures : Adverse Drug Reactions and Medications Errors, dalam Malone, P.M., Mosdell, K.W., Kier, K.L., Stonovich, J.E., (Eds) *Drug Information: A Guide For Pharmacists*, Second Edition, 481-515, The McGraw-Hill Companies, Inc., New York.
- Gould, A.B., Goodman SA, de Wolf R, 1980, Interrelation of the renin system and erythropoietin in rats. *J Lab Clin Med.*, 96:523–534 cit. Sica, D.,A., Deedwania, P., 2000, Pharmacotherapy in Congestive Heart Failure : ACE Inhibitors and Anemia, *Pharmacotherapy in Congestive Heart Failure.*, 6(6):330-332.
- Halbesma, N., Brantsma A.H., Bakker S.J., Jansen, D.F., Stolk, R.P., De Zeeuw, D., De Jong, P.E., Gansevoort, R.T., 2008, Gender differences in predictors of the decline of renal function in the general population. *Kidney Int* 2008; 74: 505–512.
- Hasanpour, M., Tootoonchi, M., Aein, F., Yadegarfar, G.H., 2006, The effects of two non-pharmacologic pain management methods for intramuscular injection pain in children, *Acute pain.*, 8: 7-12.
- HeB, E., Sperschneider, H., Stein, G., 1996, Do ACE inhibitors influence the dose of human recombinant erythropoietin in dialysis patients?, *Oxfordjournals.*, 11(4):749-751.
- Iseki, K., Iseki C., Ikemiya Y., Fukiyama K., 1996, Risk of developing end-stage renal disease in a cohort of mass screening. *Kidney Int* ; 49: 800–805.
- Joint National Committee (JNC 8), 2014, Treatment of Hypertension: JNC 8 and More, *American Society of Hypertension (ASH)*

- Joy, M.S., Kshirsagar, A., Franceschini, N., 2008, Chronic Kidney Disease: Progression-Modifying Therapies, dalam Dipiro, J.T., Talbert, R.L., Yee, Gary, C., Matzke, G.R., Wells, B.G., Posey, L.M., 2008, *Pharmacotherapy: A pathophysiologic Approach*, 8th Ed., 705-759 Thr Mcgraww-Hill, New York, USA.
- Juurlink, D.N., Mamdani, M.M., Lee, D.S., 2004, Rates of hyperkalemia after publication of randomized aldactone evaluation study, *N Engl J Med*, 351(6):543-5.
- Kajikawa, M., 1993, *Recombinant human erythropoietin and hypophosphatemia in patients with cirrhosis* dalam Sweetman, S.C., 2009, *Martindale The Complete Drug Reference*, 36th Ed., 1061, Pharmaceutical Press, USA.
- Karalliedde, L., Clarke, S.F.J., Collignon, U., Karalliedde, J., 2010, *Adverse Drug Interactions A Handbook For Prescriber*, 49, Hodder, London.
- Krapf, R., Hulter, N. H., 2009, Arterial Hypertension Induced by Erythropoietin and Erythropoiesis-Stimulating Agents (ESA), *American Society of Nephrology*, 4(2):470-80.
- Kementerian Kesehatan RI, 2013, *Hipertensi*, Pusat Data dan Informasi Kementerian Kesehatan RI, Jakarta Selatan.
- Kidney Disease Outcomes Quality Initiative (KDOQI), 2015, *Clinical Practice Guideline For Hemodialysis Adequacy: 2015 Update*, Am J Kidney Dis, National Kidney Foundation.47(3):S28-S54.896-907.
- Kidney disease informing global outcomes (KDIGO), 2012, KDIGO Clinical Practice Guideline For Anemia In Chronic Kidney Disesae, *Kidney international supplements*, 2 (4):283-309.
- Kidney disease informing global outcomes (KDIGO), 2012, KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, *Kidney international supplements*, 3(4):5-13.
- KDOQI, 2009, KDOQI Clinical Practice Guideline for Nutrition in Children with Ckd : Recommendation 6: Vitamin And Trace Element Requirements And Therapy, *American Journal of Kidney Disease, National Kidney Foundation*.
- Kidney Disease Outcomes Quality Initiative (KDOQI), 2009, KDOQI Clinical Practice Guideline for Nutrition in Children with CKD: 2008 Update, *National Kidney Foundation*. Tersedia online http://www2.kidney.org/professionals/KDOQI/guidelines_ped_ckd/cpr/6.htm 20/03/2016

Kidney Disease Outcomes Quality Initiative (KDOQI), 2002, Clinical Practice Guidelines For Chronic Kidney Disease: Evaluation, Classification and Stratification, *Am J Kidney Dis, National Kidney Foundation*.

Kidney Disease Outcomes Quality Initiative (KDOQI), 2006, Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease, *Am J Kidney Dis, National Kidney Foundation*.

Komatsu, Y., Ito, K., 1992, Erythropoietin Associated Hypertension Among Pediatric Dialysis Patients, *Adv Perit Dial.*, 8:448-52.

Lankhorst, C.E., Wish, J.B., 2010, Anemia in Renal Disease: Diagnosis and Management, *Blood Reviews.*, 24, 39–47.

Lougman, A., Ali, G.R., Abeygunasekara, S.C., 2011, comparison of The Therapeutic Efficacy of Epoietin Beta and Epoietin Alfa in Maintenance Phase Hemodialysis Patiens, *Renal Failure*, 33 (3): 373-5.

Morrone, L.F., Di Paolo, S., Logoluso, F., Schena, A., Stallone, G., Giorgino, F., Schena, F.P., 1997, Interference of angiotensin-converting enzyme inhibitors on erythropoiesis in kidney transplant recipients: Role of growth factors and cytokines, *Transplantation.*, 64:913–918.

Mozayani, A., Raymon, L., P., 2004, *Handbook Of Drug Interactions : A Clinical and Forensis Guide*, 26-28, Humana Press, United State of America.

Naranjo, C.A., Busto, U., Sellers, E.M., Sandor, P., 1981, A method for estimating the probability of adverse drug reactions. *Clin Pharmacol Ther.*, 30: 239-245 cit. Lorensia, A., Beny, C., Rizka, I.W., 2013, Analisis Adverse Drug Reactions pada Pasien Asma di Suatu Rumah Sakit Surabaya, *Jurnal Farmasi Indonesia, Ikatan Apoteker Indonesia*, 144, PT ISFI, Jakarta.

Ng, T., Marx, G., Littlewood, T., Macdougall, I., 2002, Recombinant erythropoietin in clinical practice, *Postgrad Med Journal*, 79(933): 367–376.

Palmer, B.F., 2004, Current concepts: Managing hyperkalemia caused by inhibitors of the renin angiotensin aldosterone system, *N Engl J Med*. 351:543–551.

PERNEFRI, 2013, Konsensus Hemodialisis, *Perhimpunan Nefrologi (PERNEFRI)*, Jakarta, 3-48.

- PERNEFRI, 2012, Program Indonesian Renal Registry, 5th Report Of Indonesian Renal Registry.
- PERNEFRI, 2011, Konsensus Manajemen Anemia Pada Penyakit Ginjal Kronik, *Perhimpunan Nefrologi (PERNEFRI)*, Jakarta, 3-48.
- Petar, S., Đ., Živka Đ., Aleksandar J., Jelena T., Jovan P., and Nada D., 2014, Influence Of Hemodialysis Duration Per Week On Parameters Of Dialysis Adequacy And Cardiovascular Morbidity, *Med Pregl.*, 67(11-12):385-91.
- Pisioni, R.L., Bragg-Gresham, J.L., Young, E.W., Akizawa, T., Asano, Y., Locatelli, F., Bommer, J., Cruz, J.M., Kerr, P.G., Mendelssohn, D.C., Held, P.J., Port, F.K., 2004, Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). *American Journal of kidney disease*, 44, 94-111.
- Prest, M., Kristanto, F.C., Tan, C.K., 2003, *Reaksi Obat Yang Tidak Dikehendaki*, dalam Aslam, M., Tan, C.K., Prayitno, A., *Farmasi klinis menuju pengobatan rasional dan penghargaan pilihan pasien*, 8, PT.Elex Media Komputindo kelompok Gramedia, Jakarta.
- Qureshi, I.Z., Abid, K., Ambreen, F., Qureshi, A.L., 2007, Angiotensin converting enzyme inhibitors impair recombinant human erythropoietin induced erythropoiesis in patients with chronic renal failure, *Saudi Med J.*, 28(2):193-6.
- Rowland, M., & Tozer TN, 1995, *Clinical Pharmacokinetics: Concepts and Application's*, 3rd ed., Lippincott Williams and Wilkins, A Wolters Kluwer Co., Philadelphia.
- Saudan P., Halabi, G., Perneger, T., Wasserfallen, J.P., Martin, P.Y., 2006, ACE inhibitors or angiotensin II receptor blockers in dialysed patients and erythropoietin resistance, *J Nephrol.*, 19(1):91-6.
- Suega, K., Bakte M., Dharmayuda T.G., Lukman J.S., Suwitra K., 2005, Profile of Anemia in Chronic Renal Failure Patients: Comparison Between Predialyzed and Dialyzed Patients at The Division of Nephrology Department of Internal Medicine, Sanglah Hospital, Denpasar, Bali, Indonesia, *Acta Med Indones-Indones J Intern Med*, 37(4):190-4.
- Sweetman, S.C., 2009, *Martindale The Complete Drug Reference*, 36th Ed, 1061-1064, Pharmaceutical Press, USA.

- Schiff, H., Bergner, A., 1999, *Angiotensin-II, renal anemia and hyporesponsiveness to recombinant human erythropoietin* *Int J Artif Organs* ;22(10):672–5 dalam Aronson, J.K., 2006, *Meyler's side effects of Drugs* edisi 7, 1248, Elsevier oxford, United Kingdom.
- Stockley, I.H, Lee, A., 2001, *Drug-Drug Interactions*, dalam Van Boxtel, C.J., Santoso, B., Edward, I.R., *Drug Benefits and Risks International Textbook of Clinical Pharmacology*, Jhon Wiley dan Sons.LTD., 211-224.
- Storring, P.L., Tiplady, R.J., Gaines Das R.E., Stenning B.E., Lamikanra A., 1998, Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties, *British Journal of Haematology*, 100, 79-89.
- Tan, C.K., Prayitno, A., 2003, *Perkembangan farmasi Klinis*, dalam Aslam, M., Tan, C.K. Prayitno, A., *farmasi klinis menuju pengobatan rasional dan penghargaan pilihan pasien*, 8, PT.Elex Media Komputindo kelompok Gramedia, Jakarta.
- Takamatsu, N., Abe, H., Tominaga, T., Nakahara, K., Ito, Y., Okumoto, Y., Kim, J., Kitakaze, M., Doi, T., 2009, Risk factors for chronic kidney disease in Japan: a community-based study. *BMC Nephrol*.
- USRDS, 2015^a, Annual Data Report, Volume 2 – ESRD in the United States : Chapter 1: Incidence, Prevalence, Patient Characteristics, and Treatment Modalities.
- USRDS, 2015^b, Annual Data Report, Volume 2 - ESRD in the United States : Chapter 1: Mortality.
- Van Boxtel, C.J., Santoso, B., Edward, I.R., 2001, *Drug Benefits and Risks International Textbook of Clinical Pharmacology*, 211-224 ; 291-313, Jhon Wiley dan Sons.LTD, USA.
- Weiner, D.E., Tighiouart H., Vlagopoulos P.T., 2005, Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease. *American Journal of kidney disease* 16, 03–10.
- Weiss, G., Victor, R.G., Hersko, C., 2005, Taylor and Francis Group LLC, United State of America; xvii-xxi dalam Dipiro, J.T., Talbert, R.L., Yee, G.C., Matzke, G.R., Wells, B.G., Posey, L.M., 2008, *Pharmacotherapy: A Pathophysiologic Approach*, 7th Ed., 745-764 The McGraw-Hill Companies, Inc., USA.

World Health Organization (WHO), 2011, Haemoglobin Concentrations for the Diagnosis of Anaemia and Assessment of Severity, Vitamin and Mineral Nutrition Information System, Geneva, (WHO/NMH/NHD/MNM/11.1)
<http://www.who.int/vmnis/indicators/haemoglobin 19/04/2015>

Zhang, Q., Hong, L., Lee, W., Miao, Z., Yan, C., Yongman, L., Zufu, M., Chen, Y., Lv, Y., Ma, Z., 2012, Hyperkalemia of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in hemodialysis: A meta-analysis, *J Huazhong Univ Sci Technolog Med Sci*, 32(5):785-92.